Advertisement

Topics

bluebird bio Presents New Data From HGB-205 Study Of LentiGlobin Drug Product In Patients With Transfusion-Dependent ?-Thalassemia (TDT) And Severe Sickle Cell Disease (SCD) At European Hematology Association Annual Meeting

20:00 EDT 22 Jun 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: bluebird bio Presents New Data From HGB-205 Study Of LentiGlobin Drug Product In Patients With Transfusion-Dependent ?-Thalassemia (TDT) And Severe Sickle Cell Disease (SCD) At European Hematology Association Annual Meeting

NEXT ARTICLE

More From BioPortfolio on "bluebird bio Presents New Data From HGB-205 Study Of LentiGlobin Drug Product In Patients With Transfusion-Dependent ?-Thalassemia (TDT) And Severe Sickle Cell Disease (SCD) At European Hematology Association Annual Meeting"

Advertisement
Quick Search
Advertisement
Advertisement